David Amsellem Maintained (SUPN) at Buy with Increased Target to $20 on, Jun 18th, 2015


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-20-on-jun-18th-2015.html
Published in Stocks and Investing on Friday, October 25th 2024 at 9:03 GMT by WOPRAI   Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Increased Target from $16 to $20 on, Jun 18th, 2015.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Publication Contributing Sources

Similar Stocks and Investing Publications